ReShape Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Paul Hickey

Chief executive officer

US$158.1k

Total compensation

CEO salary percentage	84.2%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Hickey's remuneration changed compared to ReShape Lifesciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$71m
Mar 31 2022	n/a	n/a	-US$65m
Dec 31 2021	n/a	n/a	-US$62m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	n/a	n/a	-US$22m
Sep 30 2020	n/a	n/a	-US$38m
Jun 30 2020	n/a	n/a	-US$62m
Mar 31 2020	n/a	n/a	-US$74m
Dec 31 2019	n/a	n/a	-US$74m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$35m
Dec 31 2018	n/a	n/a	-US$38m
Sep 30 2018	n/a	n/a	-US$42m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$30m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$29m
Jun 30 2017	n/a	n/a	-US$25m
Mar 31 2017	n/a	n/a	-US$23m
Dec 31 2016	US$389k	US$278k	-US$23m

Compensation vs Market: Paul's total compensation ($USD158.08K) is below average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Hickey (57 yo)

less than a year

Tenure

US$158,078

Compensation

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dan Gladney	Executive Chair	7.2yrs	US$95.26k	0.17% $ 6.1k
Paul Hickey	CEO, President & Director	less than a year	US$158.08k	no data
Thomas Stankovich	Chief Financial Officer	3.3yrs	US$555.84k	1.28% $ 44.7k
Mark Knudson	Co-Founder and Special Advisor to the CEO	no data	US$2.45m	no data
Katherine Tweden	Co-Founder	no data	US$400.95k	no data
Al Diaz	Vice President of Operations and R&D	1.4yrs	no data	no data
Dov Gal	VP of Regulatory Clinical Quality & Compliance Officer	no data	no data	no data
Jody Dahlman	Director of Communications	no data	no data	no data
Naqeeb Ansari	Senior Vice President of Global Commercial Operations	less than a year	US$1.16m	no data

0.5yrs

Average Tenure

61yo

Average Age

Experienced Management: 24O's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Dan Gladney	Executive Chair	7.2yrs	US$95.26k	0.17% $ 6.1k
Paul Hickey	CEO, President & Director	less than a year	US$158.08k	no data
Gary Blackford	Independent Lead Director	6.4yrs	US$77.00k	0% $ 0
Philip Schauer	Member of Scientific Advisory Board	4.6yrs	no data	no data
Scott Shikora	Member of Scientific Advisory Board	4.6yrs	US$892.19k	no data
Lori McDougal	Independent Director	7.5yrs	US$57.50k	0% $ 0
Jaime Ponce	Member of Scientific Advisory Board	4.6yrs	no data	no data
John Morton	Member of Scientific Advisory Board	4.6yrs	no data	no data
Natan Zundel	Member of Scientific Advisory Board	4.6yrs	no data	no data
Arda Minocherhomjee	Independent Director	4.4yrs	US$52.50k	no data

4.6yrs

Average Tenure

64yo

Average Age

Experienced Board: 24O's board of directors are considered experienced (4.6 years average tenure).

ReShape Lifesciences Management

Management criteria checks 3/4

Key information

Recent management updates

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

Insufficient new directors

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

High number of new directors

Recent updates

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc. Provides Revenue Guidance

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Full year 2021 earnings released: US$5.00 loss per share (vs US$3.12 loss in FY 2020)

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age